KRAS-specific Amino Acid Substitutions are Associated With Different Responses to Chemotherapy in Advanced Non-small-cell Lung Cancer.

Date publication

août 2018

Journal

Clinical lung cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEAU-FALLER Michèle , Pr CHENARD Marie-Pierre , Pr FALCOZ Pierre-Emmanuel , Dr MENNECIER Bertrand

Tous les auteurs :
Renaud S, Guerrera F, Seitlinger J, Reeb J, Voegeli AC, Legrain M, Mennecier B, Santelmo N, Falcoz PE, Quoix E, Chenard MP, Weingertner N, Beau-Faller M, Massard G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30217639

Résumé

Emerging data highlight different clinical behaviors according to KRAS amino acid substitutions (AASs) in patients with non-small-cell lung cancer (NSCLC). We aimed to evaluate whether different KRAS AASs were associated with different responses to chemotherapy.

Mots clés

Amino-acid substitution, Chemotherapy, KRAS, Lung cancer, Response

Référence

Clin Lung Cancer. 2018 Aug 22;: